Market Research Industry Reports

Ipsen SA (IPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA (IPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13
Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ipsen SA, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18
Ipsen Acquires Oncology Assets from Merrimack Pharma 20
Venture Financing 22
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24
Rhythm Pharma Raises US$33 Million In Series B Financing 26
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28
Rhythm Pharma Raises US$9.5 Million In Venture Financing 30
Partnerships 31
Arix Bioscience and Ipsen Enter into Co-Development Agreement 31
Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32
Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33
Ipsen Partners with Oncodesign 34
Ipsen Enters into Research Agreement with PeptiMimesis 35
Ipsen Enters into Research Agreement with Aepodia 36
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37
Ipsen Enters into Research Agreement with Interprotein 38
Ipsen and EpiVax Enter into Partnership 39
Ipsen Enters into Research Agreement with Hannover Medical School 40
Ipsen Enters into Research Agreement with Harvard University 41
Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 42
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 43
Ipsen Extends Distribution Agreement with Galderma for Dysport 44
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 46
Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 47
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 48
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 49
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 50
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinsons Disease 51
Ipsen Extends Distribution Agreement With Galderma For Dysport 53
Oncodesign Enters into Research Agreement with Ipsen 54
Licensing Agreements 55
Merrimack Pharma Enters into Licensing Agreement with Ipsen 55
Ipsen Amends Licensing Agreement with Exelixis 56
Ipsen Enters into Licensing Agreement with 3B Pharma 57
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58
Lexicon Pharma Expands Licensing Agreement with Ipsen 59
Otonomy Enters into Licensing Agreement with Ipsen 60
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61
Ipsen Enters into Licensing Agreement with Probi 63
Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64
Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65
Equity Offering 66
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66
Debt Offering 68
Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68
Asset Transactions 69
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69
Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For US$300 Million 71
Acquisition 73
Ipsen to Acquire Equity Stake in Akkadeas Pharma 73
Ipsen Acquires Canbex Therapeutics 74
Ipsen Acquires OctreoPharm Sciences for USD57 Million 75
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 76
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78
Ipsen SA - Key Competitors 79
Ipsen SA - Key Employees 80
Ipsen SA - Locations And Subsidiaries 82
Head Office 82
Other Locations & Subsidiaries 82
Affiliate 84
Joint Venture 84
Recent Developments 85
Financial Announcements 85
Feb 15, 2018: Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018 85
Jul 27, 2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017 87
Apr 27, 2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1 95
Feb 23, 2017: Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017 98
Corporate Communications 106
Mar 13, 2018: Ipsen Announces Executive Leadership Appointments 106
Jan 26, 2018: Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer 107
Jan 12, 2018: Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America 108
Apr 14, 2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer 109
Feb 06, 2017: Ipsen announces appointment of Dr. Sotirios G. Stergiopoulos as Head of Global Medical Affairs 110
Jan 20, 2017: Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises 111
Product News 112
07/21/2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 112
06/01/2017: Ipsen To Present New Data on Investigational Compound Lu-OPS201 at ASCO 113
04/17/2017: Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research 114
03/09/2017: Ipsen announces presentation on the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 115
Product Approvals 116
Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 116
Mar 28, 2017: NICE says pancreatic cancer drug is not cost effective for routine NHS use 118
Mar 13, 2017: Shires Onivyde Rejects For Use Within NHS Scotland 119
Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC 120
Clinical Trials 121
Jun 01, 2017: Ipsen Announces Presentation of New Data on Irinotecan at ASCO 121
May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis 122
Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies 123
Mar 27, 2017: Merrimack to Present Data on MM-398 at the 2017 American Association for Cancer Research Annual Meeting 125
Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis 126
Appendix 128
Methodology 128
About GlobalData 128
Contact Us 128
Disclaimer 128

List Of Tables

List of Tables
Ipsen SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13
Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18
Ipsen Acquires Oncology Assets from Merrimack Pharma 20
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24
Rhythm Pharma Raises US$33 Million In Series B Financing 26
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28
Rhythm Pharma Raises US$9.5 Million In Venture Financing 30
Arix Bioscience and Ipsen Enter into Co-Development Agreement 31
Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32
Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33
Ipsen Partners with Oncodesign 34
Ipsen Enters into Research Agreement with PeptiMimesis 35
Ipsen Enters into Research Agreement with Aepodia 36
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37
Ipsen Enters into Research Agreement with Interprotein 38
Ipsen and EpiVax Enter into Partnership 39
Ipsen Enters into Research Agreement with Hannover Medical School 40
Ipsen Enters into Research Agreement with Harvard University 41
Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 42
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 43
Ipsen Extends Distribution Agreement with Galderma for Dysport 44
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 46
Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 47
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 48
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 49
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 50
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinsons Disease 51
Ipsen Extends Distribution Agreement With Galderma For Dysport 53
Oncodesign Enters into Research Agreement with Ipsen 54
Merrimack Pharma Enters into Licensing Agreement with Ipsen 55
Ipsen Amends Licensing Agreement with Exelixis 56
Ipsen Enters into Licensing Agreement with 3B Pharma 57
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58
Lexicon Pharma Expands Licensing Agreement with Ipsen 59
Otonomy Enters into Licensing Agreement with Ipsen 60
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61
Ipsen Enters into Licensing Agreement with Probi 63
Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64
Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66
Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69
Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For US$300 Million 71
Ipsen to Acquire Equity Stake in Akkadeas Pharma 73
Ipsen Acquires Canbex Therapeutics 74
Ipsen Acquires OctreoPharm Sciences for USD57 Million 75
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 76
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78
Ipsen SA, Key Competitors 79
Ipsen SA, Key Employees 80
Ipsen SA, Subsidiaries 82
Ipsen SA, Affiliate 84
Ipsen SA, Joint Venture 84

List Of Figures

List of Figures
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13

Ipsen SA (IPN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel

USD 250View Report

Ipsen S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Ipsen S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Ipsen S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350View Report

Ipsen SA (IPN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel

USD 250View Report

Ipsen SA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Ipsen SA Company Profile is a detailed strategic and analytical report on Ipsen SA. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :128
Country :France
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube